文献速递产科母胎医学

呋塞米降低产前重度高血压:一项随机安慰剂对照试验

Furosemide to lower antenatal severe hypertension: a randomized placebo-controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-03-12

本研究为双盲随机安慰剂对照试验,纳入65例急性发作、重度产前高血压且脉压差≥60 mm Hg的孕妇,在首选降压药基础上加用静脉呋塞米40 mg或安慰剂。主要结局即干预后1小时平均收缩压两组无显著差异(呋塞米组147 vs 安慰剂组152 mm Hg,P=.200);呋塞米组2小时收缩压和脉压差均降低。结论认为单次静脉呋塞米是达到血压控制的合理辅助手段,尤其对疑似容量增加者。

要点

  • 急性重度产前高血压且脉压差≥60 mm Hg者,加用静脉呋塞米40 mg未显著降低1小时平均收缩压。
  • 呋塞米组2小时收缩压139 vs 安慰剂组154 mm Hg(P=.007),2小时脉压差55 vs 67(P=.003)。
  • 新发高血压亚组2小时收缩压和脉压差显著降低,原有高血压亚组未见显著降低。

核心结论

  • 静脉呋塞米联合首选降压药未显著降低给药后1小时收缩压,但呋塞米组2小时收缩压和脉压差均降低。
  • 作者认为单次静脉呋塞米是达到血压控制的合理辅助手段,尤其对疑似容量增加的患者。

研究设计与样本

  • 双盲随机安慰剂对照试验,2021年1月至2022年3月共随机65例,呋塞米组33例、安慰剂组32例。
  • 干预为在首选降压药基础上给予静脉呋塞米40 mg或安慰剂;计划每组35例以检测15 mm Hg的血压差异。
  • 主要结局为干预后第1小时平均收缩压;次要结局包括相应舒张压、干预后2小时收缩压/舒张压/脉压差、从入选血压的总降幅、血压控制持续时间、1小时内额外降压药需求、电解质和尿量。

主要发现

  • 主要结局1小时平均收缩压呋塞米组147(14.8)vs 安慰剂组152(13.8)mm Hg,P=.200。
  • 2小时收缩压呋塞米组139(18.5)vs 安慰剂组154(18.4)mm Hg,P=.007;2小时脉压差呋塞米组55(12.5)vs 安慰剂组67(15.1),P=.003。
  • 亚组分析显示新发高血压患者2小时收缩压和2小时脉压差显著降低,原有高血压患者未见显著降低。
  • 呋塞米组尿量更多,干预前后电解质和肌酐无差异。
  • 基线特征两组相似。

临床怎么用

  • 作者认为单次静脉呋塞米是达到血压控制的合理辅助手段,尤其对疑似容量增加的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertensive disorders of pregnancy are a leading cause of perinatal morbidity, and timely treatment of severely elevated blood pressure is recommended to prevent serious sequelae. In acute hypertension marked by increased blood volume, it is unknown whether diuretics used as an adjunct to antihypertensive medications lead to more effective blood pressure control. OBJECTIVE: This study aimed to evaluate whether the addition of intravenous furosemide to first-line antihypertensive agents reduces systolic blood pressure in acute-onset, severe antenatal hypertension with wide (≥60 mm Hg) pulse pressure. STUDY DESIGN: In this double-blinded randomized trial, participants received 40 mg of intravenous furosemide or placebo in addition to a first-line antihypertensive agent. The primary outcome was mean systolic blood pressure during the first hour after intervention. Secondary outcomes included corresponding diastolic blood pressure; systolic blood pressure, diastolic blood pressure, and pulse pressure at 2 hours after intervention; total reduction from qualifying blood pressure; duration of blood pressure control; need for additional antihypertensive doses within 1 hour; and electrolytes and urine output. A sample size of 35 participants per group was planned to detect a 15-mm Hg difference in blood pressure. RESULTS: Between January 2021 and March 2022, 65 individuals were randomized: 33 to furosemide and 32 to placebo. Baseline characteristics were similar between the groups. There was no difference in the primary outcome of mean 1-hour systolic blood pressure (147 [14.8] vs 152 [13.8] mm Hg; P=.200). We found a reduction in 2-hour systolic blood pressure (139 [18.5] vs 154 [18.4] mm Hg; P=.007) and a decrease in 2-hour pulse pressure (55 [12.5] vs 67 [15.1]; P=.003) in the furosemide group. Subgroup analysis according to hypertension type showed a significant reduction in 2-hour systolic blood pressure and 2-hour pulse pressure among patients with new-onset hypertension, but not among those with preexisting hypertension. Urine output was greater in the furosemide group, with no difference in electrolytes and creatinine before and after intervention. CONCLUSION: Intravenous furosemide in conjunction with a first-line antihypertensive agent did not significantly reduce systolic blood pressure in the first hour after administration. However, both systolic blood pressure and pulse pressure at 2 hours were decreased in the furosemide group. These findings suggest that a 1-time dose of intravenous furosemide is a reasonable adjunct to achieve blood pressure control, particularly in patients in whom increased volume is suspected.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Maykin MM, Mercer E, Saiki KM, et al. Furosemide to lower antenatal severe hypertension: a randomized placebo-controlled trial. Am J Obstet Gynecol MFM. 2024. PMID: 38485054. doi:10.1016/j.ajogmf.2024.101348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。